Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies if itacitinib plus standard of care treatment may help prevent graft-versus-host-disease (GVHD) in patients who have received an allogeneic (donor) stem cell transplant. An allogeneic transplant uses blood-making cells from a family member or unrelated donor to remove and replace a patient's abnormal blood cells. Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Giving itacitinib with standard of care treatment after the transplant may stop this from happening.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To compare the 100-day acute grade 2-4 GvHD rate to matched controls. SECONDARY OBJECTIVES: I. To compare the 1-year rate of GvHD-free, relapse-free survival to matched controls. II. To assess the time to neutrophil and platelet engraftment. III. To assess the toxicity profile associated with this regimen. IV. To assess the incidence of severe grade 3-4 acute GVHD. V. To assess the incidence of limited, extensive, and moderate to severe chronic GVHD. VI. To assess the incidence of disease relapse. VII. To assess the incidence of non-relapse mortality. VIII. To assess overall survival and progression-free survival. IX. To assess immunosuppression discontinuation rate. TERTIARY OBJECTIVE (CORRELATIVE STUDY): I. Immune recovery and cytokines at various time points pre- and post- transplant OUTLINE: CONDITIONING: Patients receive busulfan intravenously (IV) over 3 hours on days -20, -13, and -6 to -3, thiotepa IV on day -7, and fludarabine IV over 1 hour on days -6 to -3. STEM CELL TRANSPLANT: Patients undergo stem cell transplant on day 0. GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4. Patients also receive itacitinib orally (PO) once daily (QD) on days 5-60 in the absence of disease progression or unacceptable toxicity. Beginning day 5 after stem cell transplant, patients also receive tacrolimus IV over 24 hours until able to tolerate oral tacrolimus, whereby patients then receive tacrolimus PO twice daily (BID). After completion of study intervention, patients are followed up at days 100, 180, and 365 after stem cell transplant. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04859946
Study type Interventional
Source M.D. Anderson Cancer Center
Status Not yet recruiting
Phase Phase 1
Start date September 1, 2021
Completion date January 1, 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT04127721 - Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Phase 2
Recruiting NCT04062266 - Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission Phase 2
Recruiting NCT03246906 - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2
Recruiting NCT04339101 - Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation Phase 2
Recruiting NCT04572815 - Ustekinumab for the Prevention of Acute Graft Versus Host Disease After Unrelated Donor Hematopoietic Cell Transplant Phase 2
Terminated NCT03195010 - Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Phase 2
Active, not recruiting NCT03895918 - Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients N/A
Recruiting NCT03207854 - Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers